Meeting
2023 ASCO Genitourinary Cancers Symposium
Management disparities in metastatic castrate-sensitive prostate cancer (mCSPC).
Authors
Nataliya Mar
University of California Irvine Medical Center, Orange, CA
Nataliya Mar , Dalia Kaakour
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 79)
DOI
10.1200/JCO.2023.41.6_suppl.79
Abstract #
79
Poster Bd #
D6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Enzalutamide, docetaxel and androgen deprivation (ENZADA trial) for metastatic castrate sensitive prostate cancer (mCSPC).
First Author: Earle F Burgess
Poster
2023 ASCO Annual Meeting
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Charles J. Ryan
Poster
2023 ASCO Genitourinary Cancers Symposium
The comprehensive analysis of relationship between gut microbiome and treatment outcome of androgen deprivation therapy (ADT)-based treatment in patients with metastatic castration-sensitive and -resistant prostate cancer.
First Author: Nobuaki Matsubara
Poster
2021 Genitourinary Cancers Symposium
Prescribing patterns in patients with metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Nataliya Mar